List of Healthcare Companies with Phase 3 Active Clinical Trial - 11

Every day in the US, approximately 34 patients are removed from the transplant waiting list either because they die or they become too sick to receive a transplant. Our mission is to bring that number down to zero by developing innovative technology and services that will extend the safe preservation times for unused kidneys.

We are dedicated to transforming lives by improving the journey to a healthy, beautiful smile. Discover your straight path to a bright future at Align Technology. As a part of our smart, diverse and fast-moving global team, you'll make an impact on the market leader that's moving an industry forward. Want to find out what's next for us—and for you? Follow us on LinkedIn for business updates and check out our current opportunities at www.aligntech.com/careers. 25 years ago, we pioneered the market for clear aligners. Since then, we have continuously innovated with new products and technologies that revolutionize treatments for doctors and their patients. Today, doctors and labs in over 100 markets use the Invisalign system, iTero intraoral scanners and exocad software to improve smiles for patients – from simple tooth alignment to complex corrections, kids to adults, orthodontics to multi-disciplinary restorative treatment. Learn more about Align Technology and our products: www.aligntech.com www.invisalign.com www.itero.com www.exocad.com

Allurion was founded in 2009 with one mission: end obesity. The Allurion Program combines medical, digital, and nutritional approaches and engages an entire team to jumpstart weight loss and form lifelong healthy habits. Allurion has already helped thousands of people around the world lose weight, develop lifelong healthy habits, and transform their lives, with over 100,000 balloons placed, and over 1,000,000kg lost worldwide.

BIOHM optimizes digestive health by combining good bacteria, good fungi and enzymes to break down digestive plaque, allowing for total gut balance. This allows BIOHM's 30 billion live active cultures to maintain, support, and promote the balance of the total microbiome in the digestive system.

Cambridge Medical Robotics was created to bring the benefits of minimal access surgery to millions more patients each year. The company'saim is to make minimal access surgery available to all by delivering a robotic tool that empowers surgeons and delivers value-driven outcomes for healthcare providers.

Freenome is a private biotech company focused on developing blood tests to detect cancer early and make screening accessible for everyone.

Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities and outpatient cardiac and vascular labs, Fresenius Medical Care North America provides coordinated healthcare services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world's largest fully integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals. For more information, visit the FMCNA website at https://fmcna.com/.

IQVIA applies data science to the continuous advancement of human science to make health care decisions more precise, relevant, and even creative.

OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. OncoHost’s proprietary platform, PROphet®, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphet® NSCLC test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage.

Pierre Fabre Group held by the Pierre Fabre Foundation, is a worldwide company with a unique positioning : the alliance of pharmaceutical and dermocosmetics expertise. This makes Pierre Fabre Group : 💊 A pharmaceutical group with a strong positioning : medical and natural 🥈 The second largest dermo-cosmetics laboratory in the world 🥈 The second largest private French pharmaceutical group 🥇 The market leader in France for products sold over the counter in pharmacies. Our portfolio includes several medical franchises and international brands including ; Pharmaceutical Care Pierre Fabre Oncologie Pierre Fabre Dermatologie Naturactive Eau Thermale Avène Klorane Ducray René Furterer A-Derma Pierre Fabre Oral Care Glytone (US) Darrow (Brasil) Established in the Occitanie region since its creation, we manufacture over 95% of our products in France. We keep innovating passionately with our teams in 2 innovation centers in Brasil and Japan as well as in 6 R&D centers in France. Thanks to our 9,600 employees in 44 subsidiaries and our distribution activities in 120 countries, our group generated €2.7 billion in revenues in 2022, 69% of which is from international business. Pierre Fabre Group has a unique company structure. 86% of the Pierre Fabre Group is held by the Pierre Fabre Foundation, a government-recognized public-interest foundation, while a smaller share is owned by its employees via an employee stock ownership plan. In 2020, the independent organization ECOCERT Environment awarded Pierre Fabre's CSR policy at "excellence" level : - Excellence being the highest maturity level of the ECOCERT 26000 standard.

The Vitrolife Group is a world-leading global provider of medical devices and genetic testing testing solutions. Dedicated to the reproductive-health market since 1994, we have grown by focusing on product development, groundbreaking research, consistent quality control and acquisitions of innovative companies in the industry. In 2021, Vitrolife acquired Igenomix, a leader in reproductive genetic testing services primarily for IVF clinics. Together we are now the Vitrolife Group, a global leader in reproductive health focused on supporting our customers and patients worldwide to improve treatment outcomes – always with sustainability in mind. Based on science and advanced research capabilities, our aim is to deliver products and services for the entire reproductive-health journey, providing consistent performance and guaranteed quality. Currently, we are approximately 1,100 people worldwide headquartered in Gothenburg, Sweden. Our products and services are available in more than 125 countries, through our own presence in more than 25 countries and a vast network of distributors for the rest of the world. We are on a mission to be the leading valued solution provider in reproductive health and to support customers with successful treatment outcomes.